These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37425733)

  • 1. SOS2 regulates the threshold of mutant
    Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
    Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
    Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
    Sheffels E; Sealover NE; Theard PL; Kortum RL
    Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
    Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
    Elife; 2020 Sep; 9():. PubMed ID: 32897190
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis.
    Ding D; Xu C; Zhang J; Zhang Y; Xue L; Song J; Luo Z; Hong X; Wang J; Liang W; Xue X
    Transl Oncol; 2024 May; 43():101895. PubMed ID: 38377935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology.
    Baltanás FC; García-Navas R; Santos E
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies.
    Sealover NE; Theard PL; Hughes JM; Linke AJ; Daley BR; Kortum RL
    bioRxiv; 2023 Jun; ():. PubMed ID: 36747633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
    Huang G; Liu X; Jiang T; Cao Y; Sang M; Song X; Zhou B; Qu H; Cai H; Xing D; Mao Y; Lin G; Liu X; Zheng X
    Am J Cancer Res; 2023; 13(9):4145-4162. PubMed ID: 37818074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
    Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Specificity of the Members of the Sos Family of Ras-GEF Activators: Novel Role of Sos2 in Control of Epidermal Stem Cell Homeostasis.
    Baltanás FC; Mucientes-Valdivieso C; Lorenzo-Martín LF; Fernández-Parejo N; García-Navas R; Segrelles C; Calzada N; Fuentes-Mateos R; Paramio JM; Bustelo XR; Santos E
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.
    Xia L; Yang F; Wu X; Li S; Kan C; Zheng H; Wang S
    Cancer Cell Int; 2021 Jul; 21(1):337. PubMed ID: 34217295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer.
    Wu Z; Zhao W; Yang Z; Wang YM; Dai Y; Chen LA
    Cancer Manag Res; 2021; 13():2025-2032. PubMed ID: 33658860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.